» Articles » PMID: 31135850

Effect of Laparoscopic Vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial

Abstract

Importance: Laparoscopic distal gastrectomy is accepted as a more effective approach to conventional open distal gastrectomy for early-stage gastric cancer. However, efficacy for locally advanced gastric cancer remains uncertain.

Objective: To compare 3-year disease-free survival for patients with locally advanced gastric cancer after laparoscopic distal gastrectomy or open distal gastrectomy.

Design, Setting, And Patients: The study was a noninferiority, open-label, randomized clinical trial at 14 centers in China. A total of 1056 eligible patients with clinical stage T2, T3, or T4a gastric cancer without bulky nodes or distant metastases were enrolled from September 2012 to December 2014. Final follow-up was on December 31, 2017.

Interventions: Participants were randomized in a 1:1 ratio after stratification by site, age, cancer stage, and histology to undergo either laparoscopic distal gastrectomy (n = 528) or open distal gastrectomy (n = 528) with D2 lymphadenectomy.

Main Outcomes And Measures: The primary end point was 3-year disease-free survival with a noninferiority margin of -10% to compare laparoscopic distal gastrectomy with open distal gastrectomy. Secondary end points of 3-year overall survival and recurrence patterns were tested for superiority.

Results: Among 1056 patients, 1039 (98.4%; mean age, 56.2 years; 313 [30.1%] women) had surgery (laparoscopic distal gastrectomy [n=519] vs open distal gastrectomy [n=520]), and 999 (94.6%) completed the study. Three-year disease-free survival rate was 76.5% in the laparoscopic distal gastrectomy group and 77.8% in the open distal gastrectomy group, absolute difference of -1.3% and a 1-sided 97.5% CI of -6.5% to ∞, not crossing the prespecified noninferiority margin. Three-year overall survival rate (laparoscopic distal gastrectomy vs open distal gastrectomy: 83.1% vs 85.2%; adjusted hazard ratio, 1.19; 95% CI, 0.87 to 1.64; P = .28) and cumulative incidence of recurrence over the 3-year period (laparoscopic distal gastrectomy vs open distal gastrectomy: 18.8% vs 16.5%; subhazard ratio, 1.15; 95% CI, 0.86 to 1.54; P = .35) did not significantly differ between laparoscopic distal gastrectomy and open distal gastrectomy groups.

Conclusions And Relevance: Among patients with a preoperative clinical stage indicating locally advanced gastric cancer, laparoscopic distal gastrectomy, compared with open distal gastrectomy, did not result in inferior disease-free survival at 3 years.

Trial Registration: ClinicalTrials.gov Identifier: NCT01609309.

Citing Articles

Comparative study of ICG and non-ICG-guided laparoscopic gastrectomy for gastric cancer: a propensity score-matched analysis at a single center.

Van Du N, Anh Tuan N, Ngoc Cuong L BMJ Surg Interv Health Technol. 2025; 7(1):e000313.

PMID: 40051652 PMC: 11883552. DOI: 10.1136/bmjsit-2024-000313.


Development of a prognostic oxidative stress-immune-inflammation score and online calculators for predicting survival and recurrence in gastric cancer: a multicenter study.

Zheng H, Zheng H, Du X, Xu B, Hu M, Yu J Surg Endosc. 2025; .

PMID: 40050495 DOI: 10.1007/s00464-025-11596-6.


Robotic and laparoscopic gastrectomy for gastric cancer: comparative insights into perioperative performance and three-year survival outcomes.

Ushimaru Y, Omori T, Yamamoto K, Yanagimoto Y, Masuike Y, Matsuura N Gastric Cancer. 2025; .

PMID: 40009253 DOI: 10.1007/s10120-025-01601-1.


Cost-effectiveness of open vs. laparoscopic gastrectomy for locally advanced gastric cancer in China.

Lai M, Li Y, Lan N, Yuan W Sci Rep. 2025; 15(1):6714.

PMID: 40000698 PMC: 11861295. DOI: 10.1038/s41598-025-91003-1.


Evaluating the Role of Robotic Surgery Gastric Cancer Treatment: A Comprehensive Review by the Robotic Global Surgical Society (TROGSS) and European Federation International Society for Digestive Surgery (EFISDS) Joint Working Group.

Marano L, Cwalinski T, Girnyi S, Skokowski J, Goyal A, Malerba S Curr Oncol. 2025; 32(2).

PMID: 39996883 PMC: 11854667. DOI: 10.3390/curroncol32020083.


References
1.
Pocock S, Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31(1):103-15. View

2.
Huscher C, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A . Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg. 2005; 241(2):232-7. PMC: 1356907. DOI: 10.1097/01.sla.0000151892.35922.f2. View

3.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

4.
. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14(2):113-23. DOI: 10.1007/s10120-011-0042-4. View

5.
. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View